Exelixis, Inc.

Exelixis, Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative cancer therapies. The company's core focus lies in addressing difficult-to-treat cancers, with a robust portfolio of approved products and a promising pipeline of investigational agents. Its flagship products include CABOMETYX, a treatment for advanced renal cell carcinoma, and COMETRIQ, for metastatic medullary thyroid cancer, both derived from the potent tyrosine kinase inhibitor cabozantinib. Exelixis also offers COTELLIC, used in combination for advanced melanoma, and MINNEBRO, a mineralocorticoid receptor blocker approved for hypertension in Japan. The company's strategic approach involves not only advancing its internal pipeline, which features novel kinase inhibitors like zanzalintinib and XL309, but also exploring advanced modalities such as antibody-drug conjugates (ADCs) like XB010 and XB371, and bispecific antibodies like XB628. Exelixis leverages strategic collaborations and licensing agreements with leading pharmaceutical and biotechnology companies to expand its research and development capabilities and broaden the reach of its therapies. This multifaceted strategy positions Exelixis as a significant player in the oncology landscape, striving to deliver meaningful improvements for patients facing serious cancer diagnoses.